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Abstract
Background: The use of mechanical/physical devices for applying mild therapeutic hypothermia is the only
proven neuroprotective treatment for survivors of out of hospital cardiac arrest. However, this type of therapy is
cumbersome and associated with several side-effects. We investigated the feasibility of using a transient receptor
potential vanilloid type 1 (TRPV1) agonist for obtaining drug-induced sustainable mild hypothermia.
Methods: First, we screened a heterogeneous group of TRPV1 agonists and secondly we tested the hypothermic
properties of a selected candidate by dose-response studies. Finally we tested the hypothermic properties in a
large animal. The screening was in conscious rats, the dose-response experiments in conscious rats and in
cynomologus monkeys, and the finally we tested the hypothermic properties in conscious young cattle (calves
with a body weight as an adult human). The investigated TRPV1 agonists were administered by continuous
intravenous infusion.
Results: Screening: Dihydrocapsaicin (DHC), a component of chili pepper, displayed a desirable hypothermic profile
with regards to the duration, depth and control in conscious rats. Dose-response experiments: In both rats and
cynomologus monkeys DHC caused a dose-dependent and immediate decrease in body temperature. Thus in rats,
infusion of DHC at doses of 0.125, 0.25, 0.50, and 0.75 mg/kg/h caused a maximal ΔT (°C) as compared to vehicle
control of -0.9, -1.5, -2.0, and -4.2 within approximately 1 hour until the 6 hour infusion was stopped. Finally, in
calves the intravenous infusion of DHC was able to maintain mild hypothermia with ΔT > -3°C for more than 12
hours.
Conclusions: Our data support the hypothesis that infusion of dihydrocapsaicin is a candidate for testing as a
primary or adjunct method of inducing and maintaining therapeutic hypothermia.
Background
Mild therapeutic hypothermia (target temperature
between 32°C and 34°C) has emerged as an effective
treatment to improve neurological outcomes among car-
diac arrest survivors. Following publication of two pivo-
tal randomized clinical trials [1-3] mild therapeutic
hypothermia for 12 to 24 hours following cardiopul-
monary resuscitation (CPR) of out of hospital cardiac
arrest patients with shockable electrocardiography
rhythms is recommended by the European Resuscitation
Counsel (ERC) and the American Heart Association
(AHA) for prevention of neurological injury. Also, mild
therapeutic hypothermia has been suggested to improve
the outcome in other hypoxic-ischemic conditions
including acute ischemic stroke [4], acute myocardial
infarction [5], and neonatal encephalopathy [6]. At pre-
sent therapeutic hypothermia of human subjects is
obtained with a variety of methods, which combine phy-
sical cooling of the body surface or blood stream with
anesthesia and relaxation to inhibit shivering. In general
these physical/mechanical methods are cumbersome and
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associated with side-effects [7-10]. Therefore cooling of
the body by changing the temperature homeostasis with
a drug would offer an attractive alternative to the exist-
ing treatment, since it potentially would be easy to man-
age and the need for anesthesia and relaxation may be
avoided.
Temperature regulation is a complex biological pro-
cess controlled by the pre-optic area of the anterior
hypothalamus as well as peripheral thermo-sensors [11].
Recently it has been demonstrated that ion channels of
the transient receptor potential (TRP) family are pivotal
in this regulation and involved in the peripheral
mechanisms by which we sense hot and cold tempera-
tures [11,12]. A central member of the TRP family is
the transient receptor potential vanilloid type 1
(TRPV1), formerly known as the capsaicin-vanilloid
receptor-1, which was cloned in 1997 [13]. The TRPV1
receptor is widely expressed in the human body particu-
larly in “port-of-entry” tissues, the peripheral nervous
system, and in the brain [14,15]. Due to the involvement
of TRPV1 in nociception it has been widely studied as a
target for the development of drugs [16-18] especially
for the treatment of pain [19].
The TRPV1 receptor is a target for a large heteroge-
neous group of natural compounds including capsaici-
noids such as capsaicin and dihydrocapsaicin (DHC)
from chili pepper, piperine from black pepper, resinifera-
toxin (RTX), ginsenosides, evodiamine and others that
acts as agonists [20]. In addition potent synthetic agonists
have been developed including rinvanil [21], MSK-195
[22], arvanil [23], and olvanil [24]. Interestingly, adminis-
tration of TRPV1 agonists has been demonstrated to
induce hypothermia in rats [25,26]. However, it is cur-
rently not known whether this hypothermia induced by
infusion of a TRPV1 agonist can be maintained at a clini-
cally relevant duration, or whether the effect is restricted
to rodents or can be observed in large animals or humans
with a lower body surface. Importantly, agonists of
TRPV1 have been shown to display differential effects
concerning receptor desensitization [27], which may
affect the sustainability of the hypothermic properties.
The objective of the present study was to evaluate the
feasibility of pharmacologically induced hypothermia in
several species in vivo. In particular we hypothesized
that infusion of a TRPV1 agonist may control body tem-
perature in a fashion, which holds the potential for
obtaining drug induced mild therapeutic hypothermia in
survivors after out of hospital cardiac arrest.
Methods
Rat hypothermia screen model
Animals
Hypothermia screening studies of TRPV1 agonists were
performed at Pipeline Biotech AS (Trige, Denmark) and
initiated in Sprague Dawley male rats (Taconic Europe,
Lille Skensved, Denmark) aged 7-9 weeks weighing
approximately 250 grams. Animals were kept in a tem-
perature-controlled environment (20-24°C) at a 12 hour
normal dark-light cycle (lights on at 06.00 a.m.) with
free access to chow (Altromin 1324, Altromin Spezial-
futter GmbH, Lage, Germany) and UV-sterilized water.
The study was conducted in accordance with interna-
tionally accepted guidelines for the care and use of
laboratory animals and approved by the Danish Com-
mittee for Animal Research.
Surgery and infusion
Prior to the infusion, the rats were set with a jugular
vein catheter and an intraperitoneal (i.p.) chip for tem-
perature measurement. Briefly, a catheter was set in the
right jugular vein under sterile conditions in ketamine/
xylazine (Intervet Int. B.V., Boxmeer, The Netherlands)
anesthetized rats, and the catheter was externalized
through the neck to allow free movement during the
time of the infusion. Also, for monitoring of i.p. body
temperature, a chip sensor (IPTT-300, Electronic ID
Transponders, PLEXX, Elst, the Netherlands) was
inserted in the peritoneal cavity of the rats. Following
the surgery the rats were allowed to recover for 1-3
days before the start of the experiment. Then, on the
day of the infusion the rats were treated with carprofen
(5 mg/kg, Rimadyl vet.®, Pfizer Inc., NY, USA), placed in
a Culex Raturn movement responsive cage (BASi, West
Lafayette, IN, USA) and connected to the peristaltic
pump (Gilson, Villiers le Bel, France). The rats were
allowed to recover for 1 hour before body temperature
was recorded every 15 minutes starting at t = -15 min-
utes (baseline) and until t = 6 hours using the wireless
reader (BMDS DAS-6007, IPTT Data Acquisition Sys-
tem, PLEXX, Elst, the Netherlands). Rats with an initial
temperature reading below 36°C as a result of a mis-
placed chip were excluded from the experiment. The
infusion of test compounds was started at t = 0 hours
and continued for 4 hours. Rats (n = 2-6 per group)
were administered the following compounds infused at a
constant flow-rate of 2 ml/kg/h: Vehicle control (2%
polysorbate 80 (Sigma Aldrich, St. Louis, MO, USA) in
saline); Dihydrocapsaicin, 0.6 mg/kg/h (Cat. 92355,
Cayman Chemical Company, AH Diagnostics, Aarhus,
Denmark); Resiniferatoxin, 0.06 mg/kg/h (R8756, Lot.
038K1583, Sigma Aldrich, St. Louis, MO, USA); Olvanil,
3.0 mg/kg/h (A2098, Lot. 122K4620, Sigma Aldrich, St.
Louis, MO, USA); Arvanil, 3.0 mg/kg/h (A2098, Lot.
122K3420, Sigma Aldrich, St. Louis, MO, USA); Rinva-
nil, 15 mg/kg/h (Giovanni Appendino, University Del
Piemonte Orientale, Italy); MSK-195, 2 mg/kg/h (Cat.
ALX-550-396-M005, L13899, Medinova Scientific A/S,
Glostrup, Denmark). Following the infusion the animals
were euthanized by CO2.
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Dose-response of dihydrocapsaicin in rat
Animals
Dose-response experiments of DHC were performed at
University of Heidelberg, Department of Anesthesiology
(Heidelberg, Germany) and initiated in male Wistar-Han
rats (n = 30, Elevage Janvier, Le Genest St., Ille, France)
weighing 300-350 grams. Animals were kept at a humidity
of 55 ± 5% in a temperature-controlled environment (20 ±
1°C) and at a 12 hour normal dark-light cycle (lights on at
07.00 a.m.) with free access to chow (Ssniff RM/H, Ssniff
Spezialdiäten GmbH, Soest, Germany) and tap water
unless otherwise stated. All experiments were conducted
in accordance with European Communities Council Direc-
tive of 24th November 1986 (86/609/EEC) and approved
by the German governmental Animal Care Committee.
Surgery and infusion
The animals were implanted with PE-50 infusion cathe-
ter in the left femoral vein under pentobarbital anesthe-
sia. The catheter was exposed at the back of the animal
through a tunnel and secured by a Covance infusion
harness (Instech Laboratories, Plymouth Meeting, PA,
USA). Also, temperature probes (VitalView Series 4000
G2 E-Mitter, Mini Mitter Company, Bend, OR, USA)
were implanted in the peritoneal cavity. Following 24
hours of recovery the rats were treated with carprofen
(5 mg/kg i.v., Rimadyl®, Pfizer Pharma GmbH, Karlsruhe,
Germany) as analgesic treatment, connected to the infu-
sion pump (Compact infusion pump 975, Harvard
Apparatus, Holliston, MA, USA) and stratified into 5
groups (n = 6 per group) based on post-surgery body
weight. Following a 1 hour recovery period body tem-
perature was recorded telemetrically using the VitalView
system. The temperature was recorded before (t = -1 to
0 hours), during (t = 0 to 6 hours) and after (t = 6 to 10
hours) the infusion of vehicle control (2% polysorbate
80 (Fluka Chemie AG, Buchs, Switzerland) in saline) or
DHC (Cat. 92355, Cayman Chemical Company, AH
Diagnostics, Aarhus, Denmark). Solutions were infused
continuously via the femoral catheter at an infusion rate
of 0.013 ml/h in all animals with doses of DHC at 0,
0.125, 0.25, 0.50 or 0.75 mg/kg/h.
Dose-response of dihydrocapsaicin in cynomologus
monkeys
Animals
Two adult cynomologus monkey (Macaca fascicularis)
with a body weight of 3 kg (female) and 6 kg (male),
respectively, were purchased at Conghua Farm, Quigan
Town, China and Nafovanny, Long Thanh, Vietnam.
Animals were single housed at Covance GmbH facilities
(Münster, Germany) in a normal 12 hour light cycle
(lights on at 05.30 a.m.) in a climate controlled room
with >10 air changes/h and temperature and relative
humidity ranges of 19 - 25°C and 40 - 70%, respectively.
Twice daily the animals were offered a commercial pel-
let diet for primates (Ssniff P10, Ssniff Spezialdiäten
GmbH, Soest, Germany), and in addition the animals
received fresh fruit and bread as food supplement. Tap
water was provided ad libitum. The study was con-
ducted in accordance with European Communities
Council Directive of 24th November 1986 (86/609/EEC)
and International Conference on Harmonization (ICH)
guidelines and approved by the German governmental
Animal Care Committee.
Surgery and infusion
The animals were anesthetized with ketamine (Ketavet®,
Pfizer Pharmacia & Upjohn GmbH, Berlin, Germany),
atropine (Eifelfango, Bad Neuenahr, Germany) and
xylaxine (Rompun® 2%, Bayer Vital GmbH, Leverkusen,
Germany) for the implantation of the catheter and the
port system (Port-a-cath Implantable Access System,
SIMS Deltec Inc., St. Paul, MN, USA). Briefly, the port
was implanted subcutaneously in the middle of the back
and a catheter was tunneled under the skin via the
femoral vein into vena cava caudalis for intravenous
infusion. Also, the animals were implanted with a tem-
perature chip (IPTT-300 transponders, PLEXX, Elst, the
Netherlands) in the intraperitoneal cavity for measure-
ment of body temperature. Following the surgery the
animals were given analgesic treatment and allowed to
recover for 2-3 weeks. During the recovery period cathe-
ters were flushed regularly with normal saline to main-
tain the free flow of the port catheter system, and the
monkeys were allowed to adapt to the individually fitted
jacket, which covered the area above the port and stored
the infusion pump. Following recovery the conscious
and freely moving cynomologus monkeys were subjected
to a 12 hour infusion of vehicle control or DHC using a
Pegasus Pump Vario (Uno Roestvastaal BV, PX
Zevenaar, the Netherlands) fitted in a backpack system.
Studies were performed with at least three days wash-
out period between the study days, and starting with the
vehicle control followed by doses of DHC of 0.3, 0.6.,
1.2, and 1.8 mg/kg/h. The infusions were step-wised
increased into the full flow-rate such that flow-rate was
at 25% from t = 0 to 30 minutes, then 50% from t = 30
to 60 minutes, and 100% from t = 1 to 12 hours. Dihy-
drocapsaicin (Lot. 63908, Clauson Kaas AS, Farum,
Denmark) was formulated as an emulsion using 0.6%
polysorbate 80 (Fluka, Seelze, Germany) and 0.6% MCT
oil (Crodamol GTCC, Croda Inc., Snaith Goole, UK) per
3 mg/ml of DHC in 1.6% of glycerol. The vehicle con-
trol was 0.6% polysorbate 80 in 1.6% of glycerol. Tem-
perature readings were performed using a DAS-6003
Mini Power System and DASWR-6007 reader (PLEXX,
Elst, the Netherlands) at t = 0, 15, 30, 45, 60, 120, 180,
240, 300, 360, 420, 480, 540, 600, 660, 720, 735, 750,
765, 780, 840, 900, 960 minutes.
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Long-tem infusion of dihydrocapsaicin in young cattle
Animals
The calf experiments were carried out at the intensive
care facility at the Faculty of Agricultural Sciences,
Aarhus University, Denmark. Danish Holstein (Bos
taurus) calves weighing 71-86 kg were fed 4.5 kg milk-
replacer in the morning (123 g DM/kg, Friska Sød,
DLG, Copenhagen, Denmark) and starter concentrate
(maximal allowance 1000 g as fed/d, ValseStart Grøn,
Brødrene Ewers A/S, Sønderborg, Denmark). Dry feed
was removed from calves at 12.00 a.m. the day before
surgery and calves were not fed milk replacer until after
surgery. Calves were kept under a 16/8 hour light/dark
program and the rooms were heated and equipped with
mechanical ventilation. The temperature was set to 20°C
and the calves were loose housed individually and tied
for one hour per day at time of milk-feeding to get
accustomed to the experimental sampling situation.
The experimental procedures were conducted
under protocols approved by the Danish Animal Experi-
ments Inspectorate (license 2007/561-1381; Niels
B. Kristensen) and complied with the Danish Ministry
of Justice Law no 382 (June 10, 1987), Act no. 726 (Sep-
tember 9, 1993) concerning animal experimentation and
care of experimental animals.
Surgery and infusion
General anesthesia was induced by injection of xylazine
(0.15 mg/kg, i.m.) and ketamine (3 mg/kg, i.v.) and
maintained with isoflurane (2.5%). Calves were intubated
and mechanically ventilated with pure oxygen. Then, an
incision was placed medial to the right external jugular
vein and a purse string suture (4-0 Dermafil, Kruuse,
Denmark) was placed on the right common carotid
artery and subsequently a catheter was implanted
(Tygon S-54-HL,10-15 cm heparinized tip/90 cm total
length, 1.27 mm i.d. × 2.29 mm o.d., Buch & Holm AS,
Herlev, Denmark). Also, a purse string suture was
placed on the right external jugular vein and catheter
was implanted (Tygon S-54-HL, 15-22.5 cm heparinized
tip/90 cm total length, 1.27 mm i.d. × 2.29 mm o.d.).
Catheters were exteriorized at the level of the right
shoulder and protected by a patch mounted with 4 skin
sutures (Dermafil USP 2, Kruuse, Denmark). Following
surgery the catheters were flushed with saline and
blocked with saline containing 100 IU heparin/ml, 0.1%
benzyl alcohol, and 0.2% cefuroxime sodium (Zinacef®,
GlaxoSmithKline, Brøndby, Denmark) and calves were
injected with flunixin meglumin (Flunixin vet.®, ScanVet
Animal Health A/S, Fredensborg, Denmark) for 3 days
and antibiotics (Streptocillin vet.®, Boehringer Ingelheim
Denmark AS, Copenhagen, Denmark) for 5 days.
The day before each experimental sampling calves
were moved to the sampling rooms. Following shaving,
skin disinfection and injection of 3 ml of lidocaine
(Xylocain® 20 mg/ml, s.c., AstraZeneca A/S, Albertslund,
Denmark) calves were fitted with acute catheters
(Tygon, S-54-HL, 1.02 mm i.d., 1.78 mm o.d, Buch &
Holm A/S, Herlev, Denmark) inserted 15 cm into the
left jugular vein by percutaneous venipuncture using a
hypodermic needle (Mediplast AB, 2.5 × 110 mm,
Malmö, Sweden). The catheter was secured by skin
sutures and by 2 cuffs (5 mm pieces of Tygon pump
tubing, Buch & Holm A/S, Herlev, Denmark) slid over
the catheters using a pair of hemostats after removal of
the hypodermic needle. DHC (Cat. 92355, Cayman Che-
mical Company, AH Diagnostics, Aarhus, Denmark) was
dissolved in 20% polysorbate 80 (Sigma Aldrich, St.
Louis, MO, USA) in saline to a concentration of 12 mg/
ml. Solutions of DHC (n = 8) or vehicle control (n = 2)
were applied as a continuous intravenous infusion using
a peristaltic pump (Ole Dich Instrumentmakers Aps,
Hvidovre, Denmark). Data recording of temperature via
a thermocouple (MLT 1401; AD Instruments,
Chalgrove, England) in superior vena cava was initiated
1 hour before (baseline) the start of infusion of DHC
and continued for 25 hours. All calves were euthanized
at the end of each experimental sampling period.
Statistical analysis
Data are expressed as mean ± standard error (SE) and
compared by a one-way or two-way ANOVA and
appropriate post-test, unless otherwise stated. P < 0.05
was considered significant. The difference in body tem-
perature over time is expressed as area under the curve
(AUC). All statistical calculations were performed using
GraphPad Prism version 4.00 (GraphPad Software, Inc.,
San Diego, CA).
Results
Rat hypothermia screen model
We tested the ability of six TRPV1 agonists including
DHC, RTX, rinvanil, olvanil, arvanil and MSK-195 to
induce hypothermia in conscious rats by continuous
intravenous infusion. All the tested TRPV1 agonists
caused a significant decrease of the body temperature
during the 4 hours of infusion (Figure 1B, AUC, **p <
0.01), and the maximal response of all the tested ago-
nists as compared to vehicle control was reached within
1 hour of infusion (Figure 1A). Interestingly, the tested
agonists differentiated in the degree of tolerance devel-
oped towards the hypothermia inducing effect during
the infusion. Thus, apparently tolerance development
was most pronounced for arvanil with a maximal
hypothermia of 34.4°C (t = 0.75 hours) increasing to
37.5°C at the end of the infusion (t = 4 hours). Likewise,
rats treated with rinvanil and MSK-195 increased from
33.9 (t = 1.0 hours) to 35.6°C and 36.3 (t = 1.0 hours) to
37.6°C, respectively. The magnitude of the hypothermia
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effect was dose-dependent for all the tested TRPV1 ago-
nists (see below for DHC). Notably, at the tested doses
several of the TRPV1 agonists were able to cause a
decrease of body temperature ≥ -3°C (DHC, rinvanil,
arvanil, and olvanil). When the infusion was stopped we
observed a rapid return to normo-thermia in the DHC
treated rats, while a slight hyperthermia was seen in rats
treated with rinvanil. In contrast, in rats treated with
olvanil we observed a prolonged hypothermia during the
entire observation period of 6 hours. Clinical observa-
tions included redness of ears and paws, inactivity and
flat posture.
Dose-response of dihydrocapsaicin in rats
Dihydrocapsaicin caused a dose-dependent decrease in
body temperature in conscious rats by 6 hour continu-
ous intravenous infusion. As compared to vehicle con-
trol the maximal ΔT (°C) observed was -0.9 (t = 1.25
hours), -1.5 (t = 1.5 hours), -2.0 (t = 1.5 hours) and -4.2
(t = 4 hours) at doses of DHC of 0.125, 0.25, 0.50, and
0.75 mg/kg/h, respectively (n = 6/group, Figure 2A).
The decrease in body temperature was significant at a
dose of DHC of 0.25 mg/kg/h and above (Figure 2B,
AUC, **p < 0.01). Notably, when tested at 0.75 mg/kg/h
infusion of DHC caused a constant ΔT ≥ -3°C from t =
1.25 to 6.50 hours. Clinical observations included
redness of ears and paws, inactivity and flat posture and
were dose-dependent i.e. most pronounced at the high-
est doses tested.
Dose-response of dihydrocapsaicin in cynomologus
monkeys
Repeated administration of DHC by 12 hour continuous
intravenous infusion caused a dose-dependent decrease
in body temperature in conscious cynomologus mon-
keys. I.e. as compared to the vehicle control situation
the maximal ΔT (°C) observed was -0.7 (t = 1 hours),
-0.8 (t = 2 hours), -1.7 (t = 7 hours) and -4.0 (t = 4
hours) at doses of DHC of 0.3, 0.6, 1.2, and 1.8 mg/kg/
h, respectively (Figure 3A). The decrease in body tem-
perature was significant at a dose of DHC of 1.2 mg/kg/
h and 1.8 mg/kg/h as evaluated by the area under the
curve (Figure 3B, *p < 0.05). Notably, we observed
development of some tolerance as well as a slight end-
infusion hyperthermia when the monkeys were given
the highest dose of DHC of 1.8 mg/kg/h. Clinical obser-
vations were evident only at the doses of 1.2 and 1.8
mg/kg/h and included flushing and inactivity.
Long-tem infusion of dihydrocapsaicin in young cattle
Figure 4 summarizes infusion rate as well as the body tem-
perature measured from t = -1 to 24 hours in calves
Figure 1 Effect of TRPV1 agonist on temperature in rat. (A) Temperature profiles for transient receptor potential vanilloid type 1 agonists
dihydrocapsaicin, resiniferatoxin, olvanil, arvanil, MSK-195 and rinvanil, and vehicle control during 4 hour intravenous administration to conscious
rats. (B) Area under the curve during the infusion (t = 0 to 4 hours). Statistics: Each of the transient receptor potential vanilloid type 1 agonists
were compared to the vehicle control by an unpaired student’s t-test ***p < 0.001, **p < 0.01. Values are expressed as average ± SE, with n = 2
- 6, see Methods for further details.
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Figure 2 Hypothermic effects of DHC infusion in rats. (A) Dose-response temperature profiles in conscious rats during 6 hour intravenous
infusion of the transient receptor potential vanilloid type 1 agonist dihydrocapsaicin at doses of 0.125, 0.25, 0.50, and 0.75 mg/kg/h. (B) Area
under the curve during the infusion (t = 0 to 6 hours). Statistics: Each of the transient receptor potential vanilloid type 1 agonists were
compared to the vehicle control by an unpaired student’s t-test ***p < 0.001, **p < 0.01. Values are expressed as average ± SE, with n = 5, see
Methods for further details.
Figure 3 Hypothermic effects of DHC infusion in monkeys. (A) Dose-response temperature profiles in conscious cynomologus monkeys
during 12 hour repeated intravenous infusions of the transient receptor potential vanilloid type 1 agonist dihydrocapsaicin at doses of 0.3, 0.6,
1.2, and 1.8 mg/kg/h. (B) Area under the curve during the infusion (t = 0 to 12 hours). Statistics: Each of the transient receptor potential vanilloid
type 1 agonists were compared to the vehicle control by a one-way ANOVA followed by Dunnett’s post-test ***p < 0.001, *p < 0.05. Values are
expressed as average ± SE, with n = 2, see Methods for further details.
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treated with DHC or vehicle control. When young cattle
were treated with DHC we observed an immediate and
statistically significant decrease in body temperature from
a baseline of approximately 39°C reaching the target ΔT of
-3 to -5°C (shaded area) at t = 1.25 hour (***p < 0.01). The
maximal ΔT of -4°C compared to vehicle control was
observed after 4 hours infusion and the temperature
remained at target until t = 13 hours in calves treated with
DHC. When the infusion of DHC was stopped, the body
temperature increased rapidly and to a level at approxi-
mately 0.5°C higher than that of control, though this was
not statistically significant (p = ns). Clinical observations
included panting, salvation/lacrimation, flushing and
apparent discomfort and were evident especially in the
first hour of the infusion were the dose administered was
at 1.0 mg/kg/h, after this initial phase all clinical observa-
tions became less pronounced.
Discussion
In the present study we demonstrate that continuous
infusion of DHC, a TRPV1 receptor agonist, can induce
a sustainable and clinically relevant mild hypothermia in
rats, cynomologus monkeys, and in young cattle. In
addition we show that also synthetic TRPV1 agonists
such as MSK-195, olvanil, arvanil or rinvanil are able to
produce hypothermia in rats. Similar, TRPV1 antago-
nists have been shown to induce hyperthermia in rats as
well as in humans [28], which collectively demonstrate
the central role of TRPV1 channels in the regulation of
body temperature [11].
Based on death certificates, sudden cardiac arrest
accounts for about 15% of all death in Western coun-
tries [29] and about 330,000 per year in the United
States alone [30]. With the witness of a cardiac arrest
and performance of CPR with return of spontaneous
circulation (ROSC), mild therapeutic hypothermia has
been shown to improve survival and neurological out-
come [2]. At present the only therapy available is
mechanical/physical cooling, which is associated with
side-effects including pneumonia, sepsis, and stress-
related shivering [7]. Moreover, it can be argued that
mechanical cooling is connected to various practical
issues that may affect the frequency of which the treat-
ment is actually applied. Finally, the on-set of the use of
mechanical cooling may take several hours following the
ischemic insult [1-3], which in turn may affect the out-
come of the treatment. Taken together there is an un-
met medical need for the development of drug-induced
mild therapeutic hypothermia, which may lead to a
safer, manageable, and instant treatment immediately
following ROSC. In animals drug-induced hypothermia
has previously been demonstrated by activation of a
number of biological systems located in the brain
including the CB1 receptor [31,32], neurotensin receptor
[33], muscarine receptor [34], and 5-HT-1A receptor
[35]. Here we focused our efforts on the TRPV1 recep-
tor agonists and investigated the feasibility of a long-
term infusion-based method for chemically induced
hypothermia.
Previously it has been shown that single administra-
tion of capsaicin, DHC, and RTX [25,26] can induce a
short period of hypothermia in rats. In addition to the
role in thermoregulation, the TRPV1 receptor is
important in the sensation of pain and it contributes
to the detection of noxious heat, which in turn may
lead to effects on the cardiovascular and respiratory
systems [36]. In the current study focused on tempera-
ture regulation, we in general did not observe any
major behavioral changes that may indicate any of
these effects, except in calves during the first 1 to 2
hours of the infusion, where some discomfort was
observed indicating a pain reaction. Our findings may
be explained by relatively low dose levels tested, or the
fact that DHC was administered by the intravenous
route, which could cause a relative distribution of
DHC to central receptors possibly less involved in
nociception. On the other hand, intravenous infusion
of the TRPV1 agonist capsaicin was previously shown
to cause a hypertension and tachycardia in anesthe-
tized dogs [37]. Since the possible effect of DHC on
the cardiovascular and system is central in understand-
ing the therapeutic potential of the compound, the
issue is currently a subject for specific studies. Notably,
preliminary results demonstrate a dose-dependent
Figure 4 Hypothermic effects of DHC infusion in monkeys.
Temperature profiles in conscious calves during intravenous infusion
of various amounts of the transient receptor potential vanilloid type
1 agonist dihydrocapsaicin (n = 8) or control (n = 2). Target
temperature of ΔT = -3 to -5°C are shown as shaded area. Statistics:
Blood temperature was compared by a 2-way ANOVA followed by
Bonferroni’s post-test: ***p < 0.001 at t = 0.5 to 14 hours. Values are
expressed as average ± SE, see Methods for further details.
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cardiovascular effect including tachycardia and hyper-
tension by continuous intravenous infusion of DHC
[38]. Also, future studies may address possible adverse
effects of infusion of DHC on coagulopathy, hematolo-
gical effects, liver enzymes, and fluid and electrolyte
shifts.
Besides the ability of inducing hypothermia per se to
the relevant therapeutic level of 32-34°C, it is pivotal for
a novel drug for the treatment of patients following
ROSC after cardiac arrest, that mild therapeutic
hypothermia can be sustained for an appropriate period
of time. Thus, the current recommendation from ERC/
AHA concerning the length of period of therapeutic
hypothermia is 12-24 hours. Now, exposure of a TRPV1
agonist to the receptor may cause desensitization of the
receptor [27], and accordingly repeated dosing may lead
to a less pronounced hypothermic response as observed
in young non-naïve animals [39]. In fact, very high
exposure of a TRPV1 agonist may even lead to nerve
fiber degeneration and subsequent re-innervation [40].
Here we investigated the possibility of sustaining
hypothermia by applying various TRPV1 agonists by a
continuous intravenous infusion to adult rats. Interest-
ingly, our data indicate that the role of desensitization
vary among the heterogeneous class of TRPV1 agonists,
as it has previously been indicated in vitro in patch
clamp studies [27]. Thus, infusion of arvanil caused a
rapid desensitization towards the hypothermic effect,
which was also seen at lower dose of arvanil (data not
shown), whereas infusion of olvanil or DHC did not.
Interestingly, olvanil caused a prolonged hypothermia
even after the infusion was stopped, whereas the
hypothermic effect of DHC was short-lasting after stop-
ping the infusion. It is currently not known what causes
this differential desensitization effect, but it may relate
to the binding of the agonist to the receptor and/or the
associated permeability of the ion channel [19,41].
Another possibility is that the observed difference in the
pharmacological response of the various TRPV1 agonists
is caused by different pharmacokinetic properties of the
tested TRPV1 agonists.
From our initial screening of hypothermic properties
DHC displayed a desirable profile showing a relevant
and sustainable level of hypothermia as well as a rapid
and controllable on- and off-set, and this candidate was
therefore selected for further dose-response testing. An
important component in the regulation of human body
temperature is the ability to sweat, which causes heat
loss via evaporative cooling. In contrast, in most animals
including rats sweating does not contribute significantly
to the body temperature homeostasis, but other
mechanisms, such as panting, are important [42]. There-
fore we included dose-response studies in rats as well as
in cynomologus monkeys, the latter animal which in
contrast to rats possesses the ability to sweat [43]. We
observed that infusion of DHC caused a dose-dependent
decrease in temperature in both rats and cynomologus
monkeys. Notably, while the maximal response was at
the same level, the sensitivity towards DHC was about
3-fold higher in the rats than in cynomologus monkeys.
The reason for this is not clear, but may relate to the
role of desensitization [39], since the cynomologus mon-
keys were dosed on repeated occasions, whereas the rats
were all naïve to DHC. It may also be explained by spe-
cies differences in the molecular structure of the TRPV1
receptor [19] or the components of thermoregulation
[42,43]. Finally, it may play a role that DHC was formu-
lated in different vehicles in the two experiments, which
may have resulted in a difference in the exposure of the
compound. In this context it is of interest that when the
cynomologus monkeys, yet naïve to DHC, were treated
for the first time at the dose of 0.3 mg/kg/h, the
response was still less pronounced than rats treated with
0.25 mg/kg/h. This may indicate that desensitization is
not the only reason for the observed difference in the
hypothermic response.
Both rats and monkeys are small animals compared to
humans. In order to test the hypothermic properties of
DHC in a large animal at the weight of a human being,
we infused DHC to young cattle. We were able to sus-
tain hypothermia at the relevant therapeutic level for
more than 12 hours. It should be noted that despite a
constant infusion of compound, there was a minor
incline in body temperature during that last hours of
the infusion. Also, it is important to notice that we saw
a minor overshoot in the body temperature after discon-
tinuation of the infusion. Likewise a minor overshooting
was observed in the cynomologus monkeys following
the highest dose (1.8 mg/kg/h) applied. The reason for
this overshooting is not clear at present, and it is not
known whether or not it may be prevented by a gradual
discontinuation of the infusion or by the treatment of
the fever with non-steroidal anti-inflammatory drugs or
similar. Also, due to technical limitations here we report
only peripheral body temperatures, whereas the brain
temperature, was not assessed. These matters should be
subject of further experimentation.
In rat models of ischemia a beneficial effect of mild
hypothermia on neurological outcome has been demon-
strated by infusion of the neurotensin receptor agonist
NT77 [44] or a cannabinod (CB) receptor agonist WIN
55,212-2 [45]. However, the use of a CB1 agonist for
inducing hypothermia may be connected with undesir-
able cardiac and respiratory side-effects [46,47]. In the
present study we demonstrate for the first time that a
sustainable mild therapeutic hypothermia relevant for
the human situation can be obtained in rodents and
small and large non-rodents. Interestingly, feasibility
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studies in a rat model of cardiopulmonary resuscitation
have demonstrated that infusion of DHC can also
induce mild hypothermia in this model, and in a similar
fashion to the one reported here [38].
Conclusions
Taken together our data support the hypothesis that
infusion of dihydrocapsaicin is a candidate for testing as
a primary or adjunct method of inducing and maintain-
ing therapeutic hypothermia.
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